Licensing & Royalties >> Licensing Opportunities >> Abstract Details   Recombineering Vector Description of Invention: Transgenic mouse models have become a common experimental tool for unraveling gene function. Bacterial artificial chromosome (BAC) mediated transgenesis has proven to be a highly reliable way to obtain accurate transgene expression for in vivo studies of gene expression and function. A rate-limiting step in characterizing large numbers of genes by this approach has been the speed and ease by which BACs can be modified. NIH investigators have developed a highly efficient recombineering vector that can be used for modifying BACs in bacteria. This new vector contains tetracycline and chloramphenical resistance as well as the ccdB gene that encodes a protein that interferes with E. coli DNA gyrase. This vector can be propagated in ccdB resistant E. coli strains but not in other strains (DH5a, Top10, DH10B, etc) unless the ccdB is replaced by DNA inserts flanked by attB1 and attB2 sites. This vector was generated to modify BAC plasmids by RecA-mediated recombination. The vector disclosed here bypasses the rate-limiting step in recombineering protocols; the efficient cloning of a modifying vector. It is well suited for efficient production of engineered BACs for use in a variety of in vivo studies. Applications: The fusion of fluorescent protein or cre recombinase genes to a gene of interest. Generation of dominant negative mutations. Introduction of gene mutations that would mimic disease conditions. Insertion of lox sites for conditional deletion of transgenes. Generation of knock-out or knock-in constructs Inventors: Rafael C. Casellas and Susan E. Lim (NIAMS) Patent Status: DHHS Reference No. E-026-2009/0 -- Research Material Patent protection is not being pursued for this technology. Licensing Status: Available for Biological Material Licensing. Collaborative Research Opportunity: The NIAMS/NIH Genomics and Immunity group is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the engineering of mouse transgenic constructs using the new vector and BAC recombineering. Please contact Rafael Casellas, Ph.D. at 301-402-7858 or email to casellar@mail.nih.gov for more information. Portfolios: Devices/Instrumentation Devices/Instrumentation-Research Materials-Methods of Using Research Tools Devices/Instrumentation-Research Materials For Additional Information Please Contact: Sury Vepa PhD NIH Office of Technology Transfer 6011 Executive Blvd, Suite 325 Rockville, MD 20852-3804 Phone: 301/435-5020 Email: vepas@mail.nih.gov Fax: 301/402-0220 Web Ref: 1867 Last Updated On: 1/09